These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 37790935)

  • 1. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of prognostic model of bladder cancer based on apoptosis-related genes, in which P4HB promotes BLCA progression.
    Zou Z; Li Z; Sun W; Gao W; Liu B; Liu J; Guo Y
    BMC Urol; 2023 Oct; 23(1):167. PubMed ID: 37845668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P4HB: A novel diagnostic and prognostic biomarker for bladder carcinoma.
    Wu Y; Peng Y; Guan B; He A; Yang K; He S; Gong Y; Li X; Zhou L
    Oncol Lett; 2021 Feb; 21(2):95. PubMed ID: 33376528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
    J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a propionate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis in bladder cancer.
    Zheng F; Wang Z; Li S; Xiong S; Yuan Y; Zeng J; Tan Y; Liu X; Xu S; Fu B
    Eur J Med Res; 2024 Jul; 29(1):393. PubMed ID: 39075554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.
    Chen D; Cao H; Zheng X; Wang H; Han Z; Wang W
    BMC Cancer; 2024 Aug; 24(1):1024. PubMed ID: 39160525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer.
    Wang J; Tan Z; Huang Y; Li C; Zhan P; Wang H; Li H
    Aging (Albany NY); 2024 Jul; 16(14):11385-11408. PubMed ID: 39033778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
    BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
    Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
    Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients.
    Feng D; Li L; Li D; Wu R; Zhu W; Wang J; Ye L; Han P
    Eur J Med Res; 2023 Jul; 28(1):245. PubMed ID: 37480146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis.
    Lin Y; Li T; Li Z; Shen C; Wu Z; Zhang Z; Li Z; Yang S; Wang Z; Li P; Fu C; Guo J; Hu H
    Front Genet; 2023; 14():1097179. PubMed ID: 37091788
    [No Abstract]   [Full Text] [Related]  

  • 18. Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
    Gao W; Zhang J; Tian T; Fu Z; Bai L; Yang Y; Wu Q; Wang W; Guo Y
    PeerJ; 2023; 11():e15284. PubMed ID: 37123010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
    Chen L; Lin J; Wen Y; Chen Y; Chen CB
    Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
    Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
    Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.